Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022 · Nature Medicine · 325 citations
https://doi.org/10.1038/s41591-022-01829-9
S
Shannon M. Pfeiffer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
505
Citations
6
h-index
4
i10-index
Shannon M. Pfeiffer is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics. The author has an h-index of 6, co-authored 12 publications.
ORCID: 0000-0002-4291-9483Papers by this author
worksPrior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
2023 · Cancer Cell · 72 citations
https://doi.org/10.1016/j.ccell.2023.03.010
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
2021 · Regular and Young Investigator Award Abstracts · 1 citations
https://doi.org/10.1136/jitc-2021-sitc2021.343
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat